Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria
Abstract The 2023 ACR/EULAR criteria for antiphospholipid syndrome (APS) have modified the laboratory domain. However, enzyme-linked immunosorbent assay (ELISA) remains the sole specified method for antiphospholipid antibody detection. This study aims to establish moderate and high levels of anticar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-04097-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231309785366528 |
|---|---|
| author | Haiyue Jiang Yaqing Yang Zihan Tang Haoyu Pan Honglei Liu Xiaobing Cheng Yutong Su Junna Ye Qiongyi Hu Jianfen Meng Huihui Chi Zhuochao Zhou Jinchao Jia Hui Shi Chengde Yang Jialin Teng Tingting Liu |
| author_facet | Haiyue Jiang Yaqing Yang Zihan Tang Haoyu Pan Honglei Liu Xiaobing Cheng Yutong Su Junna Ye Qiongyi Hu Jianfen Meng Huihui Chi Zhuochao Zhou Jinchao Jia Hui Shi Chengde Yang Jialin Teng Tingting Liu |
| author_sort | Haiyue Jiang |
| collection | DOAJ |
| description | Abstract The 2023 ACR/EULAR criteria for antiphospholipid syndrome (APS) have modified the laboratory domain. However, enzyme-linked immunosorbent assay (ELISA) remains the sole specified method for antiphospholipid antibody detection. This study aims to establish moderate and high levels of anticardiolipin(aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI) using chemiluminescence assay (CIA) and to investigate the diagnostic efficiency and risk stratification capabilities of CIA in comparison to ELISA. We conducted a comprehensive analysis involving 166 APS patients, 194 disease controls, and 120 healthy controls. Our assessment entailed the utilization of both ELISA and CIA to detect aCL IgG/IgM and anti-β2GPI IgG/IgM. We established distinct moderate and high semi-quantitative thresholds for CIA corresponding to ELISA. Additionally, we computed the likelihood ratios at various thresholds and compared them with ELISA. The qualitative agreement and quantitative correlation between CIA and ELISA were robust. When applying the established moderate and high thresholds of aCL/aβ2GPI IgG/IgM in CIA according to the equal ROC specificity corresponding to ELISA, the diagnostic efficiency and risk stratification capabilities of CIA aligned comparably with those of ELISA. Although IgM exhibited poorer performance in risk assessment compared to IgG, it still played as risk factors for thrombosis and obstetrical manifestations. Utilizing the established moderate/high thresholds for aCL/aβ2GPI IgG/IgM by CIA, effectively addressing both diagnostic and risk stratification requirements comparable to ELISA, signifies that the CIA has emerged as an alternative for aPL detection. The high specificity and clinical relevance of aCL/aβ2GPI IgM in clinical events highlight its importance in clinical practice. |
| format | Article |
| id | doaj-art-3b2ed77f10164f5c9a29f1f934310472 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-3b2ed77f10164f5c9a29f1f9343104722025-08-20T02:03:35ZengNature PortfolioScientific Reports2045-23222025-05-0115111210.1038/s41598-025-04097-yDetection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteriaHaiyue Jiang0Yaqing Yang1Zihan Tang2Haoyu Pan3Honglei Liu4Xiaobing Cheng5Yutong Su6Junna Ye7Qiongyi Hu8Jianfen Meng9Huihui Chi10Zhuochao Zhou11Jinchao Jia12Hui Shi13Chengde Yang14Jialin Teng15Tingting Liu16Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineAbstract The 2023 ACR/EULAR criteria for antiphospholipid syndrome (APS) have modified the laboratory domain. However, enzyme-linked immunosorbent assay (ELISA) remains the sole specified method for antiphospholipid antibody detection. This study aims to establish moderate and high levels of anticardiolipin(aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI) using chemiluminescence assay (CIA) and to investigate the diagnostic efficiency and risk stratification capabilities of CIA in comparison to ELISA. We conducted a comprehensive analysis involving 166 APS patients, 194 disease controls, and 120 healthy controls. Our assessment entailed the utilization of both ELISA and CIA to detect aCL IgG/IgM and anti-β2GPI IgG/IgM. We established distinct moderate and high semi-quantitative thresholds for CIA corresponding to ELISA. Additionally, we computed the likelihood ratios at various thresholds and compared them with ELISA. The qualitative agreement and quantitative correlation between CIA and ELISA were robust. When applying the established moderate and high thresholds of aCL/aβ2GPI IgG/IgM in CIA according to the equal ROC specificity corresponding to ELISA, the diagnostic efficiency and risk stratification capabilities of CIA aligned comparably with those of ELISA. Although IgM exhibited poorer performance in risk assessment compared to IgG, it still played as risk factors for thrombosis and obstetrical manifestations. Utilizing the established moderate/high thresholds for aCL/aβ2GPI IgG/IgM by CIA, effectively addressing both diagnostic and risk stratification requirements comparable to ELISA, signifies that the CIA has emerged as an alternative for aPL detection. The high specificity and clinical relevance of aCL/aβ2GPI IgM in clinical events highlight its importance in clinical practice.https://doi.org/10.1038/s41598-025-04097-yAntiphospholipid syndromeAntiphospholipid autoantibodiesIgMChemiluminescence assayEnzyme-linked immunosorbent assay |
| spellingShingle | Haiyue Jiang Yaqing Yang Zihan Tang Haoyu Pan Honglei Liu Xiaobing Cheng Yutong Su Junna Ye Qiongyi Hu Jianfen Meng Huihui Chi Zhuochao Zhou Jinchao Jia Hui Shi Chengde Yang Jialin Teng Tingting Liu Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria Scientific Reports Antiphospholipid syndrome Antiphospholipid autoantibodies IgM Chemiluminescence assay Enzyme-linked immunosorbent assay |
| title | Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria |
| title_full | Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria |
| title_fullStr | Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria |
| title_full_unstemmed | Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria |
| title_short | Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria |
| title_sort | detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 aps classification criteria |
| topic | Antiphospholipid syndrome Antiphospholipid autoantibodies IgM Chemiluminescence assay Enzyme-linked immunosorbent assay |
| url | https://doi.org/10.1038/s41598-025-04097-y |
| work_keys_str_mv | AT haiyuejiang detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT yaqingyang detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT zihantang detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT haoyupan detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT hongleiliu detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT xiaobingcheng detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT yutongsu detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT junnaye detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT qiongyihu detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT jianfenmeng detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT huihuichi detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT zhuochaozhou detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT jinchaojia detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT huishi detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT chengdeyang detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT jialinteng detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria AT tingtingliu detectionofmoderatetohighantiphospholipidantibodiesbychemiluminescencemeets2023apsclassificationcriteria |